Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma

June 8th 2021

The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.

Talquetamab at RP2D Elicits High Clinical Response Rate in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.

Teclistamab Demonstrates Encouraging Efficacy, Safety at the RP2D in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.

Cilta-Cel Demonstrates Durable Responses at 18 Months in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

KCd Consolidation Does Not Show Noninferiority to ASCT in Transplant-Eligible, Newly Diagnosed Myeloma

June 8th 2021

The 2-year progression free survival achieved with carfilzomib, cyclophosphamide, and dexamethasone consolidation did not prove to be noninferior to up-front autologous stem cell transplantation in newly diagnosed, transplant-eligible patients with multiple myeloma, although the margin is small.

FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma

June 7th 2021

Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.

CART-ddBCMA Elicits 100% ORR in Relapsed/Refractory Multiple Myeloma

June 6th 2021

The autologous CAR T-cell product CART-ddBCMA was found to elicit a 100% objective response rate in patients with relapsed/refractory multiple myeloma, with deep and durable responses noted in those with poor prognostic factors.

Allogeneic HCT Plus Reduced Intensity Conditioning With Bortezomib Triplet Is Safe in Multiple Myeloma

June 5th 2021

Allogeneic hematopoietic cell transplantation was safe when used with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan in patients with high-risk multiple myeloma.

Deep Responses Yielded by Cilta-Cel in Relapsed/Refractory Multiple Myeloma

June 4th 2021

Deep and early responses were yielded with a single infusion of ciltacabtagene autoleucel in patients with previously treated, relapsed/refractory multiple myeloma.

Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma

June 4th 2021

The CAR T-cell therapy idecabtagene vicleucel continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.

Newly Approved Regimens for Relapsed/Refractory Multiple Myeloma

June 4th 2021

Key opinion leaders discuss newly approved agents and their impact on treatment decisions for relapsed/refractory multiple myeloma.

Risk of Myeloma Relapse After Frontline Therapy

June 4th 2021

Myeloma experts, Drs James Hoffman and Joshua Richter, discuss the factors that increase a patient’s risk of relapse after frontline treatment for multiple myeloma.

Dr. Ghosh on the Role of Off-the-Shelf CAR T-Cell Therapy in Myeloma

June 3rd 2021

Monalisa Ghosh, MD, discusses the role of off-the-shelf CAR T-cell therapy in patients with multiple myeloma.

Dr. Davies on Key Considerations for Early-Relapse Multiple Myeloma

June 3rd 2021

Faith Davies, MD, discusses key considerations for developing a treatment strategy for patients with early-relapse multiple myeloma.

Selinexor/Dexamethasone Combo Approved in UK for Relapsed/Refractory Myeloma

June 2nd 2021

The United Kingdom’s Medicines & Healthcare Products Regulatory Agency has granted conditional marketing authorization to the combination of selinexor and dexamethasone as a treatment for select patients with relapsed/refractory multiple myeloma.

Adjuvant Neoantigen Peptide Vaccine PGV-001 Shows Promise in Multiple Malignancies

June 2nd 2021

A personalized adjuvant neoantigen peptide vaccine, PGV-001, was successfully synthesized and administered to patients across a wide range of malignancies who had a greater than 30% chance of disease recurrence.

FDA Grants Breakthrough Status to Teclistamab for Relapsed/Refractory Multiple Myeloma

June 1st 2021

The FDA has granted a breakthrough therapy designation to teclistamab for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Ghosh on the Role of Ide-Cel in Relapsed/Refractory Multiple Myeloma

June 1st 2021

Monalisa Ghosh, MD, discusses the role of idecabtagene vicleucel in relapsed/refractory multiple myeloma landscape.

Landgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed Myeloma

May 31st 2021

Dr. Landgren discusses the potential of a quadruplet regimen comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab in the treatment of patients with newly diagnosed multiple myeloma.

Dr. Morgan on Optimizing Treatment in Ultra High–Risk Multiple Myeloma

May 27th 2021

Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.